Every week, someone asks me what is actually in the obesity pipeline. Not the headline drug. The whole field. What is recruiting, what is reading out, what quietly stalled, and what nobody is talking about yet.

For a while I answered by writing it down. The problem with writing it down is that it is wrong almost immediately. A trial changes status. A new phase 2 posts. A sponsor updates enrollment. By the time a roundup reaches an inbox, the ground has already moved. That is the quiet failure of pipeline coverage: it ages in weeks, and the reader has no way to tell how stale the version in front of them has become.

So I stopped summarizing and built the thing I actually wanted. It is a single table of every active phase 2 and phase 3 obesity drug trial, and it does not rely on my memory or my schedule. It reads directly from ClinicalTrials.gov the moment you open it. When the registry updates, the table updates. There is no version of this that is 3 weeks old.

The table pulls trials filtered on 4 conditions: the indication is obesity, the intervention is a drug, the phase is 2 or 3, and the study is still open. Open here means recruiting, not yet recruiting, enrolling by invitation, or active but no longer recruiting. Completed and terminated studies drop out, because the point of this tool is the frontier, not the archive.

Each row gives you the trial title linked straight to its registry page, its NCT identifier, recruitment status, phase, the investigational drug or drugs, the lead sponsor, target enrollment, primary completion date, and when the record was last updated. You can search across titles, drugs, and sponsors. You can filter by phase and status. You can sort any column, and you can export whatever view you have built to a CSV in 1 click. If you want to know how many phase 3 programs a given sponsor is running right now, that is 2 clicks.

I did not build a database of my opinions. I built a cleaner window onto a public one. Every figure in the table comes from the sponsor's own registry filing at ClinicalTrials.gov, the same federal record regulators and investigators use. I added the interface. I did not touch the data. That distinction is the entire point. The value here is not that I decided what matters. It is that you can see the whole field without me deciding for you.

It also means the tool inherits the registry's honest limits, and you should hold onto them. A registry lists what is being studied, not what works. Enrollment counts and recruitment status are dependable. A trial's presence tells you a molecule is being tested at scale. It tells you nothing about whether the result will be good. Efficacy, safety, and durability live in the published readout, not the listing. Read the table as a map of activity, not a scoreboard.

Open it when a drug crosses your feed and you want to know where it actually stands. Type the name. See every open trial testing it, the phase, the sponsor, the enrollment target, and when it should read out. Filter to phase 3 if you only care about programs near the finish line. Export a sponsor's active roster before a conference. It is built to answer the question you already have, faster than a search would, without the hype layer in between.

The tool is free. Open it, break it, tell me what is missing. I will keep it pointed at the frontier.

REFERENCES

1. U.S. National Library of Medicine. ClinicalTrials.gov API v2. National Institutes of Health. Data retrieved live at page load.

2. Eli Lilly and Company. TRIUMPH-1 topline results, retatrutide phase 3 program. Press-release data, May 21, 2026.